metricas
covid
Buscar en
Gastroenterología y Hepatología (English Edition)
Toda la web
Inicio Gastroenterología y Hepatología (English Edition) Serological levels of IGF-1 and IGFBP-3 in patients with Barrett's esophagus and...
Journal Information
Vol. 46. Issue 5.
Pages 360-368 (May 2023)
Share
Share
Download PDF
More article options
Vol. 46. Issue 5.
Pages 360-368 (May 2023)
Original article
Serological levels of IGF-1 and IGFBP-3 in patients with Barrett's esophagus and esophageal adenocarcinoma: Longitudinal study
Niveles séricos de IGF-1 e IGFBP-3 en pacientes con esófago de Barrett y adenocarcinoma de esófago. Estudio longitudinal
Hugo Uchimaa, Angella Da Fienoa, Araceli Bonillaa, Jordana Melo-Borgesa, Cristina Sánchez-Montesa, Míriam Cuatrecasasb,c,d, Henry Córdovaa,c, Ignasi Elizaldea,c,d, Natalia Rakislovab, Jordi Gratacós-Ginèsa, Carolina Bayarria, Gherzon Casanovaa, Àngels Ginèsa,c,d, Josep Llacha,c,d, Francesc Balaguera,c,d, Glòria Fernández-Esparracha,c,d,
Corresponding author
mgfernan@clinic.cat

Corresponding author.
a Unidad de Endoscopia, Servicio de Gastroenterología, Institut de Malalties Digestives i Metaboliques, Hospital Clínic de Barcelona, Universitat de Barcelona (UB), Barcelona, Spain
b Servicio de Anatomía Patológica, Hospital Clínic de Barcelona, Barcelona, Spain
c IDIBAPS. CIBEREHD, Barcelona, Spain
d Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), Barcelona, Spain
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (4)
Table 1. Clinical and demographic characteristics of patients with BO, control group and adenocarcinoma.
Table 2. Demographic and clinical characteristics of patients with BO separated according to whether or not they have dysplasia (including low and high grade).
Table 3. Characteristics of the 11 patients who had progression during follow-up.
Table 4. Comparative study of patients with BO who had progression during follow-up and those without progression.
Show moreShow less
Abstract
Background

Barrett's oesophagus (BE) is an entity with a known histological progression to malignancy. The Insulin-Like Growth Factor (IGF) system is involved in the carcinogenesis through obesity-related mechanisms that include IGF and it has been associated with several types of cancer.

Objectives

To evaluate the serological levels of IGF-1 and IGFBP-3 in patients with BE and esophageal adenocarcinoma.

Patients and methods

Prospective study of patients with BE and esophageal adenocarcinoma who underwent upper endoscopy between September 2012 and December 2015. A baseline determination of IGF-1 and IGFBP-3 was performed. We included a control group of patients without BE.

Results

116 patients were included: 36 controls, 62 with BE (42 without dysplasia and 20 with dysplasia) and 18 with adenocarcinoma. IGF-1 and IGF-1/IGFBP-3 mol ratio showed a progression to high levels in BE and adenocarcinoma than in controls (IGF-1: 135.55 ± 66.07 ng/mL, 148.33 ± 81.5 ng/mL, 108.19 ± 46.69 ng/mL, respectively; p = 0.049) (molar ratio: 0.23 ± 0.91, 0.29 ± 0.11, 0.19 ± 0.06, respectively; p = 0.001), without differences between the histological types of BE. Fifty-four out of the 65 patients with BE were followed up (median of 58.50 months, range 12–113) and 11 of them (20.4%) presented progression to low-grade dysplasia (n = 8) or high-grade dysplasia/adenocarcinoma (n = 3), without differences in the IGF system compared with patients without progression.

Conclusions

Patients with BE and esophageal adenocarcinoma have changes in the IGF system although the serological levels of IGF-1 and IGFBP-3 do not correlate with histological progression of BE.

Keywords:
Barrett´s esophagus
Esophageal adenocarcinoma
IGF-1
IGFBP3
Resumen
Antecedentes

El esófago de Barrett (EB) es una entidad con una progresión histológica a malignidad conocida. Los factores de crecimiento insulínico (IGF, de Insulin-Like Growth Factor) están involucrados en la carcinogénesis asociada a la obesidad y se han asociado con el riesgo de padecer algunos tipos de cáncer.

Objetivos

Evaluar los niveles serológicos de IGF-1 e IGFBP-3 en pacientes con EB y adenocarcinoma de esófago.

Pacientes y métodos

Estudio prospectivo de pacientes con EB y adenocarcinoma de esófago explorados con gastroscopia entre Septiembre 2012 y Diciembre 2015 a los que se realizó una extracción de sangre para la determinación de IGF-1 e IGFBP-3. Se incluyó un grupo control.

Resultados

Se incluyeron 116 pacientes: 36 controles, 62 con EB (42 sin displasia y 20 con displasia) y 18 con adenocarcinoma. El IGF-1 y la ratio molar IGF-1/IGFBP-3 presentaron un aumento progresivo en los grupos con EB y adenocarcinoma comparado con los controles (IGF-1: 135.55 ± 66.07 ng/mL, 148.33 ± 81.5 ng/mL, 108.19 ± 46.69 ng/mL, respectivamente; p = 0.049) (ratio molar: 0.23 ± 0.91, 0.29 ± 0.11, 0.19 ± 0.06, respectivamente; p = 0.001), sin diferencias entre los diferentes grados histológicos. 54 de los 65 pacientes con EB fueron seguidos durante una mediana de 58.50 meses (12–113) y 11 de ellos (20.4%) presentaron progresión a displasia de bajo grado (n = 8) o displasia de alto grado/adenocarcinoma (n = 3), sin encontrar diferencias en el sistema IGF comparado con los que no progresaron.

Conclusiones

los pacientes con EB y adenocarcinoma esofágico presentan cambios en el sistema IGF aunque los niveles de IGF-1 y IGFBP-3 no se correlacionan con la progresión histológica del EB.

Palabras clave:
Esófago de Barrett
Adenocarcinoma esofágico
IGF-1
IGFBP-3

Article

These are the options to access the full texts of the publication Gastroenterología y Hepatología (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Gastroenterología y Hepatología (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos